What is the optimal treatment of superior mesenteric vein/portal vein thrombosis after bariatric surgery? Is SMA-directed t-PA the answer?
Bariatric Medicine Institute, Salt Lake City, Utah.
LeGrand
L
Belnap
Bariatric Medicine Institute, Salt Lake City, Utah.
Hinali
H
Zaveri
Bariatric Medicine Institute, Salt Lake City, Utah.
Daniel
D
Cottam
Bariatric Medicine Institute, Salt Lake City, Utah.
Amit
A
Surve
Huntsman Cancer Hospital, Hematology Clinic 2 C-BMT, Salt Lake City, Utah.
George M
GM
Rodgers
Bariatric Medicine Institute, Salt Lake City, Utah.
Cara
C
Drury
D000328:Adult; D050110:Bariatric Surgery / Q000009:adverse effects*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008641:Mesenteric Vascular Occlusion / Q000188:drug therapy* / Q000209:etiology; D008642:Mesenteric Veins; D008875:Middle Aged; D011169:Portal Vein; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology; D015912:Thrombolytic Therapy / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator